Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-27T01:52:21.034Z Has data issue: false hasContentIssue false
  • English
  • Français

Nosocomial Candida guilliermondii Fungemia in Cancer Patients

Published online by Cambridge University Press:  02 January 2015

Masoud Mardani ,
Hend A. Hanna ,
Essam Girgawy  and
Issam Raad
Masoud Mardani
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Medical Specialties, Section of Infection Control, Houston, Texas
Hend A. Hanna
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Medical Specialties, Section of Infection Control, Houston, Texas
Essam Girgawy
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Medical Specialties, Section of Infection Control, Houston, Texas
Issam Raad*
Affiliation:
University of Texas M.D. Anderson Cancer Center, Department of Medical Specialties, Section of Infection Control, Houston, Texas
*
Section of Infection Control, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
Get access Rights & Permissions [Opens in a new window]

Abstract

From 1988 to 1998, we identified nine patients with Candida guilliermondii fungemia. Four of the five patients with nosocomial infection died, while all of the non-nosocomial cases survived, even though one half of them (2/4) did not receive any treatment Nosocomial C guilliermondii fungemia is often associated with poor outcome despite aggressive antifungal therapy.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 5 , May 2000 , pp. 336 - 337
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Pfaller, MA, Jones, RN, Messer, SA, Edmonds, MB, Wenzel, RP, the SCOPE Participant Group. National surveillance of bloodstream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;30:121–129.Google Scholar
2. Beck-Sague, CM, Jarvis, WR. The National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial infection in the United States, 1980-1990. J Infect Dis 1993; 167:1247–1251.CrossRefGoogle ScholarPubMed
3. Bodey, GP, Bolivar, R, Fainstein, V. Infectious complications in leukemic patients. Semin Hematol 1993;19:193–226.Google Scholar
4. Nguyen, MH, Peacock, JE, Morris, AJ, Tanner, DC, Nguyen, ML, Syndman, DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617–623.Google Scholar
5. Wingard, JR. Importance of Candida species other than C albicans as pathogen in oncology patients. Clin Infect Dis 1995;20:115–125.Google Scholar
6. Rinaldi, MG. Biology and pathogenicity of Candida species. In: Bodey, GP, ed. Candidiasis: Pathogenesis, Diagnosis and Treatment. New York, NY: Raven Press; 1993:1–20.Google Scholar
7. Hurley, R, Winner, HI. Pathogenicity in genus Candida . Mycopathologia 1964;24:337–346.Google Scholar
8. Rippon, JW. Candidiasis and the pathogenic yeast. In: Rippon, JW, ed. Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes. Philadelphia, PA: W.B. Saunders Co; 1982:565–594.Google Scholar
9. Meunier, F, Aoun, M, Bitar, N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(suppl):S120–S125.Google Scholar
10. Lecciones, JA, Lee, JW, Navarro, EE, Witebsky, FG, Marshall, D, Steinberg, SM, et al. Vascular catheter associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875–883.Google Scholar